Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

TD Cowen analysts adjusted their outlook on Biogen (NASDAQ:BIIB) shares, reducing the price target to $200 from the previous $275, while sustaining a Buy rating on the stock. The revision reflects ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Biogen (BIIB) to $157 from $192 and keeps an Equal Weight rating on the ...

Citi lowered the firm’s price target on Biogen (BIIB) to $145 from $160 and keeps a Neutral rating on the shares post the Q4 report. The ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.

Biogen UK. The software is built in a modular fashion to make it more accessible to MS professionals, letting them pick what is most relevant to their experience. Initiating dialogue with MS ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

Live sports and other programming from Eurosport will move to the TNT channels, which are operated as a joint venture between WBD and UK telco BT. Eurosport majors in cycling, tennis, winter and ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve ...

Jan 27 (Reuters) - Sage Therapeutics (SAGE.O), opens new tab said on Monday that its board has unanimously rejected Biogen’s (BIIB.O), opens new tab $469 million offer, stating it "significantly ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. The Trump administration is already making itself felt in the ...